The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
October 26th 2021
Concurrent use of tumor-treating fields, radiation therapy, and temozolomide is under study as a potential treatment for patients with newly diagnosed, stage IV glioblastoma.
October 25th 2021
Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.
October 8th 2021
The FDA has granted a rare pediatric disease designation to lutetium-177-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from Y-mAbs Therapeutics, Inc., the developer of the product.
August 30th 2021
The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with glioblastoma multiforme and other malignant gliomas.
August 25th 2021
The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven medulloblastoma
July 16th 2021
Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.
July 13th 2021
The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme.
June 25th 2021
Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
June 25th 2021
Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.
June 23rd 2021
The University of Texas MD Anderson Cancer Center is pursuing several novel approaches, including viro-immunotherapy and genetically engineered natural killer cells to treat patients with glioblastoma, while also conducting tumor analysis to better comprehend the disease.
June 11th 2021
The Japan Ministry of Health, Labour, and Welfare has granted conditional and time-limited approval to teserpaturev for the treatment of patients with malignant glioma; this is the first oncolytic virus to receive approval for use in this indication or any primary brain cancer.
June 8th 2021
The personalized cancer vaccine AV-GBM-1, developed by AIVITA Biomedical Inc., significantly improved progression-free survival over standard of care in patients with newly diagnosed glioblastoma.
June 2nd 2021
Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.
May 26th 2021
Sara M. Federico, MD, discusses risk categorization in neuroblastoma.
May 26th 2021
Standard response assessment in neuro-oncology- and immunotherapy RANO-defined progression-free did not correlate with overall survival vs modified RANO-defined PFS, which strongly correlated with OS in patients with recurrent glioblastoma treated with MDNA55 in a phase 2 trial, suggesting that mRANO may be the optimal means of therapeutic response assessment in recurrent glioblastoma.
May 21st 2021
Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.
May 18th 2021
Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.
May 15th 2021
Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.
May 10th 2021
Sara M. Federico, MD, discusses the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.